SOURCE: The Trout Group LLC

The Trout Group LLC

November 16, 2015 15:43 ET

The Trout Group to Host "Trout Talks" Key Opinion Leader Meeting and Live Webcast on November 23 in New York City

Dr. Joshua Brody of the Mount Sinai School of Medicine in New York City to Present an American Society of Hematology 2015 Preview

NEW YORK, NY--(Marketwired - November 16, 2015) - The Trout Group, the leading global investor relations and strategic advisory firm servicing the life sciences industry, will host an American Society of Hematology 2015 preview breakfast and webcast on November 23, 2015 at 9:00 am ET in New York. This preview will highlight select studies being presented at the upcoming 2015 meeting of the American Society of Hematology, as discussed by our invited faculty, Dr. Joshua Brody. This event marks the 25th presentation in Trout's Cancer Immunotherapy "Trout Talks" series. The live webcast of the event will be available at

Dr. Brody is an Assistant Professor in Hematology and Medical Oncology, and the Director of the Lymphoma Immunotherapy Program at the Mount Sinai School of Medicine in New York City. The Lymphoma Immunotherapy Program focuses on basic and applied tumor immunology, particularly in lymphoma, melanoma, and ovarian adenocarcinoma. Other areas of interest include: cancer vaccines, sequencing of the TCRbV repertoires, and studies of small-molecule inhibitors of lymphocyte signal transduction, e.g. PI3K, mTOR, and BTK.

Dr. Brody will offer his insights on the 2015 ASH abstracts most relevant to his research interests, as well as abstracts -- appropriate to Dr. Brody's skill set -- suggested beforehand by those who plan on attending live or via webcast.

The talk, moderated by Trout Group scientific advisor, Neil Canavan, will consist of a 45 minutes discussion of selected abstracts by Dr. Brody's discussion, followed by 15 minutes of questions from the audience. Questions from webcast participants should be sent to The next Trout Talk in our Cancer Immunotherapy series is scheduled for January 11, 2016 in San Francisco, CA. Investors wishing to attend these or the future events should email to RSVP or for more details.

Current clinical trials led by Dr. Brody:

In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy NCT01976585

Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma: NCT01306643

Recent publications by Dr. Brody:

In-situ tumor vaccination: Bringing the fight to the tumor. Pierce RH, Brody JD, Kohrt HE.

Hum Vaccin Immunother. 2015;11(8):1901-9.

Lymphoma: immune evasion strategies. Upadhyay R, M, Brody JD. Cancers. 2015 Apr 30;7(2):736-62..

Signaling pathways in lymphoma: pathogenesis and therapeutic targets.

Arita A, Brody JD. Future Oncol. 2013 Oct;9(10):1549-71. (Review)

About The Trout Group:

Since 1996, Trout has been the leading strategic partner to the life sciences industry, connecting companies, investors and the most exciting innovations in the sector. With a unique suite of services in investor relations, communications and financial advisory, Trout is at the intersection through which scientific advances and its network of powerful relationships can meet to create long term value for stakeholders.

Please join us at our Annual 1x1 Management Access Event in San Francisco, January 11-14, 2016:

The Trout Group is now a co-sponsor of the 'Even More of What's Hot in Immuno-Oncology Licensing" web panel. Learn from industry experts by registering here.

Contact Information